- Turkish Journal of Medical Sciences
- Vol: 50 Issue: 2
- Midkine level may be used as a noninvasive biomarker in Crohn's disease
Midkine level may be used as a noninvasive biomarker in Crohn's disease
Authors : Murat Kekilli, Alpaslan Tanoğlu, Fatih Karaahmet, Zeynal Doğan, Murat Can, Abdurrahim Sayilir, Başak Çakal, Tolga Düzenli, Yavuz Beyazit
Pages : 324-329
Doi:10.3906/sag-1904-167
View : 16 | Download : 4
Publication Date : 9999-12-31
Article Type : Makaleler
Abstract :Background/aim: Crohn's disease CD is a kind of inflammatory bowel disease. Midkine MDK is an endogenous inflammatory marker. We aimed to investigate the relationship between MDK levels and inflammation and hence determine whether MDK can be used as a noninvasive biomarker in active CD. Materials and methods: Sixty-five consecutive patients over the age of 18 with CD and 36 healthy controls were included in this study. CD patients' venous blood samples were taken before treatment. Serum MDK levels were determined in human plasma samples by enzyme-linked immunosorbent assay ELISA method. Results: The mean age of the study patients was 44.8 ± 12.5 years, 35 patients were female, and 30 were male. Of these 65 patients, 37 had active CD and 28 were in the remission phase. MDK levels were significantly higher in active and remission CD than in healthy controls P = 0.01, P = 0.038, respectively . Conclusion: We report that there is an association between MDK levels and CD activation, and therefore with enhanced inflammation. MDK levels were significantly correlated with inflammatory indices. In line with our findings, we suggest the theory that MDK inhibitors may be useful in treating Crohn's disease.Keywords : Midkine, inflammatory bowel disease, Crohn's disease, biomarker, inflammation